nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—sarcoma	0.206	1	CrCtD
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—sarcoma	0.0921	0.309	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—sarcoma	0.0881	0.295	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Etoposide—sarcoma	0.0723	0.242	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—sarcoma	0.046	0.154	CiPCiCtD
Epirubicin—liver cancer—sarcoma	0.0448	0.261	CtDrD
Epirubicin—Daunorubicin—Doxorubicin—sarcoma	0.0437	0.333	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—sarcoma	0.0437	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—sarcoma	0.0437	0.333	CrCrCtD
Epirubicin—uterine cancer—sarcoma	0.0384	0.224	CtDrD
Epirubicin—bone cancer—sarcoma	0.0345	0.201	CtDrD
Epirubicin—testicular cancer—sarcoma	0.0286	0.167	CtDrD
Epirubicin—AURKA—Doxorubicin—sarcoma	0.0258	0.201	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—sarcoma	0.0258	0.201	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—sarcoma	0.0258	0.201	CbGbCtD
Epirubicin—peripheral nervous system neoplasm—sarcoma	0.0252	0.147	CtDrD
Epirubicin—TOP2A—Mitoxantrone—sarcoma	0.0122	0.0947	CbGbCtD
Epirubicin—TOP2A—Etoposide—sarcoma	0.00767	0.0597	CbGbCtD
Epirubicin—ABCC1—Dactinomycin—sarcoma	0.00753	0.0587	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—sarcoma	0.00674	0.0525	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—sarcoma	0.00523	0.0407	CbGbCtD
Epirubicin—ABCC1—Vincristine—sarcoma	0.00464	0.0361	CbGbCtD
Epirubicin—ABCC1—Etoposide—sarcoma	0.00425	0.0331	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—sarcoma	0.0029	0.0226	CbGbCtD
Epirubicin—CHD1—mammary gland—sarcoma	0.000558	0.0451	CbGeAlD
Epirubicin—AURKA—mammary gland—sarcoma	0.00045	0.0364	CbGeAlD
Epirubicin—CHD1—myometrium—sarcoma	0.000396	0.032	CbGeAlD
Epirubicin—DHCR7—mammary gland—sarcoma	0.000376	0.0304	CbGeAlD
Epirubicin—CHD1—seminal vesicle—sarcoma	0.000358	0.0289	CbGeAlD
Epirubicin—YWHAG—mammary gland—sarcoma	0.000345	0.0279	CbGeAlD
Epirubicin—CHD1—hematopoietic system—sarcoma	0.00034	0.0275	CbGeAlD
Epirubicin—AURKA—myometrium—sarcoma	0.000319	0.0258	CbGeAlD
Epirubicin—AURKA—hematopoietic system—sarcoma	0.000274	0.0222	CbGeAlD
Epirubicin—CHD1—cardiac atrium—sarcoma	0.000258	0.0209	CbGeAlD
Epirubicin—CHD1—uterus—sarcoma	0.000257	0.0208	CbGeAlD
Epirubicin—YWHAG—myometrium—sarcoma	0.000245	0.0198	CbGeAlD
Epirubicin—DHCR7—seminal vesicle—sarcoma	0.000241	0.0195	CbGeAlD
Epirubicin—CHD1—lymphoid tissue—sarcoma	0.000239	0.0194	CbGeAlD
Epirubicin—DHCR7—hematopoietic system—sarcoma	0.000229	0.0185	CbGeAlD
Epirubicin—CHD1—tendon—sarcoma	0.000225	0.0182	CbGeAlD
Epirubicin—YWHAG—seminal vesicle—sarcoma	0.000221	0.0179	CbGeAlD
Epirubicin—CHD1—bone marrow—sarcoma	0.000218	0.0176	CbGeAlD
Epirubicin—YWHAG—hematopoietic system—sarcoma	0.00021	0.017	CbGeAlD
Epirubicin—AURKA—uterus—sarcoma	0.000207	0.0167	CbGeAlD
Epirubicin—YWHAG—connective tissue—sarcoma	0.000202	0.0164	CbGeAlD
Epirubicin—DHCR7—skin of body—sarcoma	0.000199	0.0161	CbGeAlD
Epirubicin—AURKA—lymphoid tissue—sarcoma	0.000193	0.0156	CbGeAlD
Epirubicin—CHD1—testis—sarcoma	0.000186	0.0151	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—sarcoma	0.000185	0.015	CbGeAlD
Epirubicin—PLA2G4A—myometrium—sarcoma	0.000183	0.0148	CbGeAlD
Epirubicin—AURKA—tendon—sarcoma	0.000181	0.0147	CbGeAlD
Epirubicin—CHD1—liver—sarcoma	0.000176	0.0142	CbGeAlD
Epirubicin—AURKA—bone marrow—sarcoma	0.000176	0.0142	CbGeAlD
Epirubicin—DHCR7—cardiac atrium—sarcoma	0.000174	0.0141	CbGeAlD
Epirubicin—TOP2A—myometrium—sarcoma	0.000174	0.014	CbGeAlD
Epirubicin—PLA2G4A—seminal vesicle—sarcoma	0.000165	0.0134	CbGeAlD
Epirubicin—DHCR7—lymphoid tissue—sarcoma	0.000161	0.0131	CbGeAlD
Epirubicin—YWHAG—cardiac atrium—sarcoma	0.00016	0.0129	CbGeAlD
Epirubicin—YWHAG—uterus—sarcoma	0.000159	0.0128	CbGeAlD
Epirubicin—PLA2G4A—hematopoietic system—sarcoma	0.000157	0.0127	CbGeAlD
Epirubicin—PLA2G4A—connective tissue—sarcoma	0.000151	0.0122	CbGeAlD
Epirubicin—AURKA—testis—sarcoma	0.00015	0.0121	CbGeAlD
Epirubicin—YWHAG—lymphoid tissue—sarcoma	0.000148	0.012	CbGeAlD
Epirubicin—DHCR7—bone marrow—sarcoma	0.000147	0.0119	CbGeAlD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—sarcoma	0.000146	0.201	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—sarcoma	0.000146	0.201	CbGdCrCtD
Epirubicin—AURKA—liver—sarcoma	0.000142	0.0115	CbGeAlD
Epirubicin—YWHAG—tendon—sarcoma	0.000139	0.0113	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—sarcoma	0.000138	0.0112	CbGeAlD
Epirubicin—CHD1—lymph node—sarcoma	0.000135	0.0109	CbGeAlD
Epirubicin—YWHAG—bone marrow—sarcoma	0.000135	0.0109	CbGeAlD
Epirubicin—DHCR7—testis—sarcoma	0.000126	0.0102	CbGeAlD
Epirubicin—DHCR7—liver—sarcoma	0.000119	0.0096	CbGeAlD
Epirubicin—YWHAG—testis—sarcoma	0.000115	0.00932	CbGeAlD
Epirubicin—TOP2A—uterus—sarcoma	0.000113	0.0091	CbGeAlD
Epirubicin—YWHAG—liver—sarcoma	0.000109	0.00881	CbGeAlD
Epirubicin—AURKA—lymph node—sarcoma	0.000109	0.0088	CbGeAlD
Epirubicin—ABCC1—myometrium—sarcoma	0.000104	0.00845	CbGeAlD
Epirubicin—UGT2B7—testis—sarcoma	0.000104	0.00842	CbGeAlD
Epirubicin—PLA2G4A—tendon—sarcoma	0.000104	0.0084	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—sarcoma	0.000101	0.00813	CbGeAlD
Epirubicin—AURKA—Teniposide—Etoposide—sarcoma	9.94e-05	0.137	CbGdCrCtD
Epirubicin—TOP2A—tendon—sarcoma	9.86e-05	0.00798	CbGeAlD
Epirubicin—UGT2B7—liver—sarcoma	9.84e-05	0.00796	CbGeAlD
Epirubicin—TOP2A—bone marrow—sarcoma	9.55e-05	0.00773	CbGeAlD
Epirubicin—ABCC1—seminal vesicle—sarcoma	9.44e-05	0.00764	CbGeAlD
Epirubicin—DHCR7—lymph node—sarcoma	9.1e-05	0.00736	CbGeAlD
Epirubicin—PLA2G4A—testis—sarcoma	8.6e-05	0.00695	CbGeAlD
Epirubicin—YWHAG—lymph node—sarcoma	8.35e-05	0.00676	CbGeAlD
Epirubicin—TOP2A—testis—sarcoma	8.17e-05	0.00661	CbGeAlD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PLCG1—sarcoma	7.5e-05	0.00671	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—PLCG1—sarcoma	7.48e-05	0.00669	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—ATF1—sarcoma	7.1e-05	0.00635	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—CCND1—sarcoma	7e-05	0.00626	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—PLCG1—sarcoma	6.97e-05	0.00624	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—sarcoma	6.86e-05	0.00613	CbGpPWpGaD
Epirubicin—ABCC1—cardiac atrium—sarcoma	6.81e-05	0.00551	CbGeAlD
Epirubicin—PLA2G4A—Ca-dependent events—CREB1—sarcoma	6.81e-05	0.00609	CbGpPWpGaD
Epirubicin—ABCC1—uterus—sarcoma	6.78e-05	0.00548	CbGeAlD
Epirubicin—YWHAG—Class I PI3K signaling events mediated by Akt—SRC—sarcoma	6.41e-05	0.00573	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—SRC—sarcoma	6.27e-05	0.0056	CbGpPWpGaD
Epirubicin—PLA2G4A—lymph node—sarcoma	6.23e-05	0.00504	CbGeAlD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—sarcoma	6.17e-05	0.00552	CbGpPWpGaD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—CREB1—sarcoma	6.16e-05	0.00551	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—NRAS—sarcoma	6.03e-05	0.00539	CbGpPWpGaD
Epirubicin—TOP2A—Vindesine—Vincristine—sarcoma	6.03e-05	0.0832	CbGdCrCtD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	6.02e-05	0.00538	CbGpPWpGaD
Epirubicin—ABCC1—tendon—sarcoma	5.94e-05	0.0048	CbGeAlD
Epirubicin—TOP2A—lymph node—sarcoma	5.92e-05	0.00479	CbGeAlD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—PLCG1—sarcoma	5.87e-05	0.00525	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—FOXO1—sarcoma	5.61e-05	0.00502	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—ATF1—sarcoma	5.58e-05	0.00499	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—CTNNB1—sarcoma	5.47e-05	0.00489	CbGpPWpGaD
Epirubicin—YWHAG—FoxO family signaling—CTNNB1—sarcoma	5.42e-05	0.00484	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—FOXO1—sarcoma	5.31e-05	0.00474	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—KRAS—sarcoma	5.19e-05	0.00464	CbGpPWpGaD
Epirubicin—PLA2G4A—ADP signalling through P2Y purinoceptor 1—SRC—sarcoma	5.08e-05	0.00455	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—STAG1—sarcoma	5.03e-05	0.0045	CbGpPWpGaD
Epirubicin—PLA2G4A—PLC beta mediated events—CREB1—sarcoma	5.01e-05	0.00448	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—FOXO1—sarcoma	5e-05	0.00447	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—PDGFRB—sarcoma	4.94e-05	0.00442	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—VEGFA—sarcoma	4.93e-05	0.00441	CbGpPWpGaD
Epirubicin—PLA2G4A—G-protein mediated events—CREB1—sarcoma	4.92e-05	0.0044	CbGpPWpGaD
Epirubicin—ABCC1—testis—sarcoma	4.92e-05	0.00398	CbGeAlD
Epirubicin—YWHAG—LKB1 signaling events—MYC—sarcoma	4.87e-05	0.00436	CbGpPWpGaD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—sarcoma	4.8e-05	0.0663	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—sarcoma	4.8e-05	0.0663	CbGdCrCtD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	4.77e-05	0.00427	CbGpPWpGaD
Epirubicin—ABCC1—liver—sarcoma	4.65e-05	0.00376	CbGeAlD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—EGFR—sarcoma	4.6e-05	0.00411	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	4.57e-05	0.00408	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—sarcoma	4.54e-05	0.00406	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—STAG1—sarcoma	4.5e-05	0.00402	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—MYC—sarcoma	4.43e-05	0.00396	CbGpPWpGaD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—sarcoma	4.42e-05	0.00395	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—sarcoma	4.41e-05	0.00394	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—EGFR—sarcoma	4.33e-05	0.00387	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	4.33e-05	0.00387	CbGpPWpGaD
Epirubicin—PLA2G4A—Signal amplification—SRC—sarcoma	4.28e-05	0.00383	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PLCG1—sarcoma	4.23e-05	0.00378	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—CREB1—sarcoma	4.13e-05	0.00369	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CREB1—sarcoma	4.07e-05	0.00364	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—sarcoma	4e-05	0.00358	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—JUN—sarcoma	3.97e-05	0.00355	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	3.95e-05	0.00354	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—NPM1—sarcoma	3.86e-05	0.00345	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—CREB1—sarcoma	3.85e-05	0.00344	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—STAG1—sarcoma	3.81e-05	0.00341	CbGpPWpGaD
Epirubicin—TOP2A—Vinorelbine—Vincristine—sarcoma	3.8e-05	0.0525	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—sarcoma	3.8e-05	0.0525	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—sarcoma	3.8e-05	0.0525	CbGdCrCtD
Epirubicin—YWHAG—mTOR signaling pathway—NRAS—sarcoma	3.71e-05	0.00332	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	3.7e-05	0.00331	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—HRAS—sarcoma	3.69e-05	0.0033	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	3.69e-05	0.0033	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	3.66e-05	0.00327	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—sarcoma	3.64e-05	0.00325	CbGpPWpGaD
Epirubicin—ABCC1—lymph node—sarcoma	3.56e-05	0.00288	CbGeAlD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—MYC—sarcoma	3.56e-05	0.00319	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—SRC—sarcoma	3.56e-05	0.00318	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MDM2—sarcoma	3.49e-05	0.00312	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—STAG1—sarcoma	3.41e-05	0.00305	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFC—sarcoma	3.41e-05	0.00305	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP2—sarcoma	3.37e-05	0.00302	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MDM2—sarcoma	3.37e-05	0.00301	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—KRAS—sarcoma	3.2e-05	0.00286	CbGpPWpGaD
Epirubicin—PLA2G4A—Opioid Signalling—CREB1—sarcoma	3.08e-05	0.00275	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—CREB1—sarcoma	3.02e-05	0.0027	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CREB1—sarcoma	3.01e-05	0.00269	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PDGFRB—sarcoma	2.99e-05	0.00268	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—JUN—sarcoma	2.97e-05	0.00265	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	2.96e-05	0.00265	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CCND1—sarcoma	2.93e-05	0.00262	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—JUN—sarcoma	2.93e-05	0.00262	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—NPM1—sarcoma	2.93e-05	0.00262	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	2.91e-05	0.0026	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	2.86e-05	0.00256	CbGpPWpGaD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—sarcoma	2.8e-05	0.0025	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	2.78e-05	0.00248	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	2.78e-05	0.00248	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—JUN—sarcoma	2.77e-05	0.00247	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—HRAS—sarcoma	2.72e-05	0.00243	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—JUN—sarcoma	2.71e-05	0.00242	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—STAG1—sarcoma	2.67e-05	0.00239	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—SRC—sarcoma	2.66e-05	0.00238	CbGpPWpGaD
Epirubicin—TOP2A—Vinblastine—Vincristine—sarcoma	2.61e-05	0.0361	CbGdCrCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—JUN—sarcoma	2.61e-05	0.00233	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—JUN—sarcoma	2.58e-05	0.00231	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—NRAS—sarcoma	2.56e-05	0.00229	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—VEGFA—sarcoma	2.56e-05	0.00229	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—HRAS—sarcoma	2.51e-05	0.00224	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—SRC—sarcoma	2.48e-05	0.00222	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—SRC—sarcoma	2.43e-05	0.00217	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	2.42e-05	0.00217	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	2.42e-05	0.00216	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TEK—sarcoma	2.39e-05	0.00214	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—STAG1—sarcoma	2.38e-05	0.00213	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MYC—sarcoma	2.35e-05	0.0021	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—SRC—sarcoma	2.34e-05	0.00209	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—EGFR—sarcoma	2.33e-05	0.00209	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—SRC—sarcoma	2.32e-05	0.00207	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—EGFR—sarcoma	2.3e-05	0.00206	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—NRAS—sarcoma	2.23e-05	0.00199	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—KRAS—sarcoma	2.2e-05	0.00197	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ANGPT2—sarcoma	2.19e-05	0.00196	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—EGFR—sarcoma	2.18e-05	0.00195	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—KRAS—sarcoma	2.17e-05	0.00194	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—JUN—sarcoma	2.17e-05	0.00194	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—JUN—sarcoma	2.16e-05	0.00193	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—CTNNB1—sarcoma	2.16e-05	0.00193	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CTNNB1—sarcoma	2.15e-05	0.00192	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	2.1e-05	0.00188	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—MYC—sarcoma	2.07e-05	0.00186	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—KRAS—sarcoma	2.06e-05	0.00184	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—EGFR—sarcoma	2.05e-05	0.00183	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—NPM1—sarcoma	2.05e-05	0.00183	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—sarcoma	2e-05	0.00179	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—ENO2—sarcoma	1.95e-05	0.00174	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—sarcoma	1.94e-05	0.00173	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—HBA1—sarcoma	1.94e-05	0.00173	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—sarcoma	1.93e-05	0.00173	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—KRAS—sarcoma	1.92e-05	0.00171	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—sarcoma	1.89e-05	0.00169	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—HRAS—sarcoma	1.87e-05	0.00168	CbGpPWpGaD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—sarcoma	1.83e-05	0.0253	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—sarcoma	1.83e-05	0.0253	CbGdCrCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.79e-05	0.0016	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFC—sarcoma	1.76e-05	0.00157	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	1.75e-05	0.00157	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—HRAS—sarcoma	1.75e-05	0.00156	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—CREB1—sarcoma	1.72e-05	0.00154	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—HRAS—sarcoma	1.71e-05	0.00153	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—sarcoma	1.7e-05	0.00152	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—SRC—sarcoma	1.66e-05	0.00148	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PLCG1—sarcoma	1.65e-05	0.00148	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—sarcoma	1.63e-05	0.00146	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—sarcoma	1.59e-05	0.00142	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—JUN—sarcoma	1.56e-05	0.0014	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.55e-05	0.00139	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.48e-05	0.00132	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—sarcoma	1.43e-05	0.00128	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—SRC—sarcoma	1.4e-05	0.00125	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PLCG1—sarcoma	1.38e-05	0.00123	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—MYC—sarcoma	1.36e-05	0.00122	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—NRAS—sarcoma	1.35e-05	0.00121	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.29e-05	0.00115	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.29e-05	0.00115	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.28e-05	0.00115	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.28e-05	0.00114	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—MYC—sarcoma	1.26e-05	0.00112	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—JUN—sarcoma	1.23e-05	0.0011	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—MDM2—sarcoma	1.21e-05	0.00108	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CCND1—sarcoma	1.18e-05	0.00105	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—sarcoma	1.16e-05	0.00104	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.15e-05	0.00103	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.12e-05	0.001	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.12e-05	0.000998	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.11e-05	0.000996	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.11e-05	0.000989	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CCND1—sarcoma	1.05e-05	0.000941	CbGpPWpGaD
Epirubicin—Purpura—Doxorubicin—sarcoma	1.04e-05	0.000259	CcSEcCtD
Epirubicin—Body temperature increased—Dactinomycin—sarcoma	1.04e-05	0.000259	CcSEcCtD
Epirubicin—Abdominal pain—Dactinomycin—sarcoma	1.04e-05	0.000259	CcSEcCtD
Epirubicin—Anaphylactoid reaction—Doxorubicin—sarcoma	1.04e-05	0.000258	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.03e-05	0.000924	CbGpPWpGaD
Epirubicin—Hypoglycaemia—Doxorubicin—sarcoma	1.03e-05	0.000256	CcSEcCtD
Epirubicin—Cardiac failure—Doxorubicin—sarcoma	1.03e-05	0.000256	CcSEcCtD
Epirubicin—Paraesthesia—Mitoxantrone—sarcoma	1.03e-05	0.000256	CcSEcCtD
Epirubicin—Loss of consciousness—Etoposide—sarcoma	1.02e-05	0.000255	CcSEcCtD
Epirubicin—Cerebrovascular accident—Doxorubicin—sarcoma	1.02e-05	0.000255	CcSEcCtD
Epirubicin—Lethargy—Doxorubicin—sarcoma	1.02e-05	0.000255	CcSEcCtD
Epirubicin—Decreased appetite—Vincristine—sarcoma	1.02e-05	0.000254	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL2—sarcoma	1.02e-05	0.000911	CbGpPWpGaD
Epirubicin—Dyspnoea—Mitoxantrone—sarcoma	1.02e-05	0.000254	CcSEcCtD
Epirubicin—Cough—Etoposide—sarcoma	1.02e-05	0.000253	CcSEcCtD
Epirubicin—Somnolence—Mitoxantrone—sarcoma	1.02e-05	0.000253	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Vincristine—sarcoma	1.01e-05	0.000252	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.01e-05	0.000904	CbGpPWpGaD
Epirubicin—Fatigue—Vincristine—sarcoma	1.01e-05	0.000252	CcSEcCtD
Epirubicin—Convulsion—Etoposide—sarcoma	1.01e-05	0.000251	CcSEcCtD
Epirubicin—Hyponatraemia—Doxorubicin—sarcoma	1.01e-05	0.000251	CcSEcCtD
Epirubicin—Dyspepsia—Mitoxantrone—sarcoma	1.01e-05	0.000251	CcSEcCtD
Epirubicin—Hypertension—Etoposide—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Constipation—Vincristine—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Pain—Vincristine—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Osteoarthritis—Doxorubicin—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Pain in extremity—Doxorubicin—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—Diplopia—Doxorubicin—sarcoma	1e-05	0.00025	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	9.99e-06	0.000894	CbGpPWpGaD
Epirubicin—Decreased appetite—Mitoxantrone—sarcoma	9.93e-06	0.000247	CcSEcCtD
Epirubicin—Chest pain—Etoposide—sarcoma	9.91e-06	0.000247	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—sarcoma	9.87e-06	0.000883	CbGpPWpGaD
Epirubicin—Migraine—Doxorubicin—sarcoma	9.86e-06	0.000246	CcSEcCtD
Epirubicin—Affect lability—Doxorubicin—sarcoma	9.86e-06	0.000246	CcSEcCtD
Epirubicin—Fatigue—Mitoxantrone—sarcoma	9.84e-06	0.000245	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	9.84e-06	0.000245	CcSEcCtD
Epirubicin—Discomfort—Etoposide—sarcoma	9.79e-06	0.000244	CcSEcCtD
Epirubicin—Pain—Mitoxantrone—sarcoma	9.76e-06	0.000243	CcSEcCtD
Epirubicin—Constipation—Mitoxantrone—sarcoma	9.76e-06	0.000243	CcSEcCtD
Epirubicin—Hypersensitivity—Thiotepa—sarcoma	9.74e-06	0.000243	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	9.73e-06	0.00087	CbGpPWpGaD
Epirubicin—Face oedema—Doxorubicin—sarcoma	9.68e-06	0.000241	CcSEcCtD
Epirubicin—Hypersensitivity—Dactinomycin—sarcoma	9.67e-06	0.000241	CcSEcCtD
Epirubicin—Gastrointestinal pain—Vincristine—sarcoma	9.59e-06	0.000239	CcSEcCtD
Epirubicin—Confusional state—Etoposide—sarcoma	9.58e-06	0.000239	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	9.55e-06	0.000854	CbGpPWpGaD
Epirubicin—Cardiac arrest—Doxorubicin—sarcoma	9.53e-06	0.000238	CcSEcCtD
Epirubicin—Anaphylactic shock—Etoposide—sarcoma	9.5e-06	0.000237	CcSEcCtD
Epirubicin—Mood swings—Doxorubicin—sarcoma	9.49e-06	0.000237	CcSEcCtD
Epirubicin—Asthenia—Thiotepa—sarcoma	9.49e-06	0.000237	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—sarcoma	9.44e-06	0.000844	CbGpPWpGaD
Epirubicin—Infection—Etoposide—sarcoma	9.44e-06	0.000235	CcSEcCtD
Epirubicin—Ataxia—Doxorubicin—sarcoma	9.42e-06	0.000235	CcSEcCtD
Epirubicin—Asthenia—Dactinomycin—sarcoma	9.41e-06	0.000235	CcSEcCtD
Epirubicin—Feeling abnormal—Mitoxantrone—sarcoma	9.41e-06	0.000235	CcSEcCtD
Epirubicin—Blood creatinine increased—Doxorubicin—sarcoma	9.39e-06	0.000234	CcSEcCtD
Epirubicin—Pruritus—Thiotepa—sarcoma	9.35e-06	0.000233	CcSEcCtD
Epirubicin—Gastrointestinal pain—Mitoxantrone—sarcoma	9.34e-06	0.000233	CcSEcCtD
Epirubicin—Dehydration—Doxorubicin—sarcoma	9.32e-06	0.000232	CcSEcCtD
Epirubicin—Thrombocytopenia—Etoposide—sarcoma	9.3e-06	0.000232	CcSEcCtD
Epirubicin—Tachycardia—Etoposide—sarcoma	9.27e-06	0.000231	CcSEcCtD
Epirubicin—Abdominal pain—Vincristine—sarcoma	9.27e-06	0.000231	CcSEcCtD
Epirubicin—Body temperature increased—Vincristine—sarcoma	9.27e-06	0.000231	CcSEcCtD
Epirubicin—Liver function test abnormal—Doxorubicin—sarcoma	9.25e-06	0.000231	CcSEcCtD
Epirubicin—Skin disorder—Etoposide—sarcoma	9.22e-06	0.00023	CcSEcCtD
Epirubicin—Dry skin—Doxorubicin—sarcoma	9.19e-06	0.000229	CcSEcCtD
Epirubicin—Hyperhidrosis—Etoposide—sarcoma	9.18e-06	0.000229	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MDM2—sarcoma	9.16e-06	0.000819	CbGpPWpGaD
Epirubicin—Abdominal pain upper—Doxorubicin—sarcoma	9.15e-06	0.000228	CcSEcCtD
Epirubicin—Orthostatic hypotension—Doxorubicin—sarcoma	9.15e-06	0.000228	CcSEcCtD
Epirubicin—Hypokalaemia—Doxorubicin—sarcoma	9.12e-06	0.000227	CcSEcCtD
Epirubicin—Urticaria—Mitoxantrone—sarcoma	9.07e-06	0.000226	CcSEcCtD
Epirubicin—Breast disorder—Doxorubicin—sarcoma	9.06e-06	0.000226	CcSEcCtD
Epirubicin—Anorexia—Etoposide—sarcoma	9.05e-06	0.000226	CcSEcCtD
Epirubicin—Diarrhoea—Thiotepa—sarcoma	9.05e-06	0.000226	CcSEcCtD
Epirubicin—Body temperature increased—Mitoxantrone—sarcoma	9.03e-06	0.000225	CcSEcCtD
Epirubicin—Abdominal pain—Mitoxantrone—sarcoma	9.03e-06	0.000225	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—sarcoma	9.02e-06	0.000225	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—sarcoma	9.02e-06	0.000225	CcSEcCtD
Epirubicin—Diarrhoea—Dactinomycin—sarcoma	8.98e-06	0.000224	CcSEcCtD
Epirubicin—Nasopharyngitis—Doxorubicin—sarcoma	8.96e-06	0.000223	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	8.95e-06	0.000801	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CCND1—sarcoma	8.92e-06	0.000798	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SRC—sarcoma	8.89e-06	0.000795	CbGpPWpGaD
Epirubicin—Hypotension—Etoposide—sarcoma	8.87e-06	0.000221	CcSEcCtD
Epirubicin—Gastritis—Doxorubicin—sarcoma	8.87e-06	0.000221	CcSEcCtD
Epirubicin—Muscular weakness—Doxorubicin—sarcoma	8.84e-06	0.00022	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—sarcoma	8.84e-06	0.00022	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	8.76e-06	0.000783	CbGpPWpGaD
Epirubicin—Dizziness—Thiotepa—sarcoma	8.74e-06	0.000218	CcSEcCtD
Epirubicin—Abdominal distension—Doxorubicin—sarcoma	8.72e-06	0.000217	CcSEcCtD
Epirubicin—Dysphagia—Doxorubicin—sarcoma	8.66e-06	0.000216	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—sarcoma	8.66e-06	0.000216	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—sarcoma	8.66e-06	0.000216	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—sarcoma	8.66e-06	0.000774	CbGpPWpGaD
Epirubicin—Hypersensitivity—Vincristine—sarcoma	8.64e-06	0.000215	CcSEcCtD
Epirubicin—Eosinophilia—Doxorubicin—sarcoma	8.58e-06	0.000214	CcSEcCtD
Epirubicin—Paraesthesia—Etoposide—sarcoma	8.53e-06	0.000213	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—sarcoma	8.49e-06	0.000212	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	8.49e-06	0.000759	CbGpPWpGaD
Epirubicin—Dyspnoea—Etoposide—sarcoma	8.47e-06	0.000211	CcSEcCtD
Epirubicin—Somnolence—Etoposide—sarcoma	8.44e-06	0.00021	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—sarcoma	8.44e-06	0.000755	CbGpPWpGaD
Epirubicin—Angina pectoris—Doxorubicin—sarcoma	8.44e-06	0.00021	CcSEcCtD
Epirubicin—Hypersensitivity—Mitoxantrone—sarcoma	8.41e-06	0.00021	CcSEcCtD
Epirubicin—Asthenia—Vincristine—sarcoma	8.41e-06	0.00021	CcSEcCtD
Epirubicin—Vomiting—Thiotepa—sarcoma	8.41e-06	0.00021	CcSEcCtD
Epirubicin—Vomiting—Dactinomycin—sarcoma	8.34e-06	0.000208	CcSEcCtD
Epirubicin—Rash—Thiotepa—sarcoma	8.34e-06	0.000208	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—sarcoma	8.33e-06	0.000208	CcSEcCtD
Epirubicin—Dermatitis—Thiotepa—sarcoma	8.33e-06	0.000208	CcSEcCtD
Epirubicin—Headache—Thiotepa—sarcoma	8.28e-06	0.000207	CcSEcCtD
Epirubicin—Rash—Dactinomycin—sarcoma	8.27e-06	0.000206	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	8.27e-06	0.00074	CbGpPWpGaD
Epirubicin—Decreased appetite—Etoposide—sarcoma	8.26e-06	0.000206	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—sarcoma	8.23e-06	0.000205	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Etoposide—sarcoma	8.2e-06	0.000204	CcSEcCtD
Epirubicin—Asthenia—Mitoxantrone—sarcoma	8.19e-06	0.000204	CcSEcCtD
Epirubicin—Fatigue—Etoposide—sarcoma	8.19e-06	0.000204	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—sarcoma	8.15e-06	0.000729	CbGpPWpGaD
Epirubicin—Constipation—Etoposide—sarcoma	8.12e-06	0.000202	CcSEcCtD
Epirubicin—Pain—Etoposide—sarcoma	8.12e-06	0.000202	CcSEcCtD
Epirubicin—Neutropenia—Doxorubicin—sarcoma	8.1e-06	0.000202	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—sarcoma	8.1e-06	0.000202	CcSEcCtD
Epirubicin—ABCC1—Disease—TLE1—sarcoma	8.05e-06	0.00072	CbGpPWpGaD
Epirubicin—Upper respiratory tract infection—Doxorubicin—sarcoma	8.05e-06	0.000201	CcSEcCtD
Epirubicin—Diarrhoea—Vincristine—sarcoma	8.02e-06	0.0002	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—sarcoma	8e-06	0.000199	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CCND1—sarcoma	7.98e-06	0.000713	CbGpPWpGaD
Epirubicin—Photosensitivity reaction—Doxorubicin—sarcoma	7.91e-06	0.000197	CcSEcCtD
Epirubicin—Weight increased—Doxorubicin—sarcoma	7.88e-06	0.000197	CcSEcCtD
Epirubicin—Nausea—Thiotepa—sarcoma	7.85e-06	0.000196	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—sarcoma	7.84e-06	0.000195	CcSEcCtD
Epirubicin—Feeling abnormal—Etoposide—sarcoma	7.83e-06	0.000195	CcSEcCtD
Epirubicin—Hyperglycaemia—Doxorubicin—sarcoma	7.81e-06	0.000195	CcSEcCtD
Epirubicin—Diarrhoea—Mitoxantrone—sarcoma	7.81e-06	0.000195	CcSEcCtD
Epirubicin—Nausea—Dactinomycin—sarcoma	7.79e-06	0.000194	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—sarcoma	7.77e-06	0.000194	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—sarcoma	7.77e-06	0.000194	CcSEcCtD
Epirubicin—Dizziness—Vincristine—sarcoma	7.75e-06	0.000193	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—sarcoma	7.72e-06	0.000193	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—sarcoma	7.72e-06	0.000193	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—sarcoma	7.72e-06	0.000193	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—sarcoma	7.66e-06	0.000191	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCR4—sarcoma	7.61e-06	0.000681	CbGpPWpGaD
Epirubicin—Renal failure—Doxorubicin—sarcoma	7.59e-06	0.000189	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—sarcoma	7.57e-06	0.000189	CcSEcCtD
Epirubicin—Urticaria—Etoposide—sarcoma	7.54e-06	0.000188	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—sarcoma	7.53e-06	0.000188	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—sarcoma	7.53e-06	0.000188	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—sarcoma	7.51e-06	0.000187	CcSEcCtD
Epirubicin—Body temperature increased—Etoposide—sarcoma	7.51e-06	0.000187	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—sarcoma	7.51e-06	0.000187	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—sarcoma	7.51e-06	0.000187	CcSEcCtD
Epirubicin—Vomiting—Vincristine—sarcoma	7.45e-06	0.000186	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—sarcoma	7.4e-06	0.000185	CcSEcCtD
Epirubicin—Rash—Vincristine—sarcoma	7.39e-06	0.000184	CcSEcCtD
Epirubicin—Dermatitis—Vincristine—sarcoma	7.39e-06	0.000184	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—sarcoma	7.36e-06	0.000184	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	7.35e-06	0.000658	CbGpPWpGaD
Epirubicin—Headache—Vincristine—sarcoma	7.34e-06	0.000183	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—sarcoma	7.3e-06	0.000182	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—sarcoma	7.28e-06	0.000182	CcSEcCtD
Epirubicin—ABCC1—Disease—NPM1—sarcoma	7.27e-06	0.00065	CbGpPWpGaD
Epirubicin—Vomiting—Mitoxantrone—sarcoma	7.26e-06	0.000181	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—sarcoma	7.25e-06	0.000181	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—sarcoma	7.21e-06	0.00018	CcSEcCtD
Epirubicin—Rash—Mitoxantrone—sarcoma	7.2e-06	0.000179	CcSEcCtD
Epirubicin—Dermatitis—Mitoxantrone—sarcoma	7.19e-06	0.000179	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—sarcoma	7.15e-06	0.00064	CbGpPWpGaD
Epirubicin—Headache—Mitoxantrone—sarcoma	7.15e-06	0.000178	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—TLE1—sarcoma	7.06e-06	0.000631	CbGpPWpGaD
Epirubicin—Bradycardia—Doxorubicin—sarcoma	7.06e-06	0.000176	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—sarcoma	7e-06	0.000174	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—sarcoma	6.97e-06	0.000174	CcSEcCtD
Epirubicin—Nausea—Vincristine—sarcoma	6.96e-06	0.000174	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—sarcoma	6.95e-06	0.000173	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—sarcoma	6.93e-06	0.000173	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—sarcoma	6.93e-06	0.000173	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—sarcoma	6.93e-06	0.00062	CbGpPWpGaD
Epirubicin—Hypoaesthesia—Doxorubicin—sarcoma	6.9e-06	0.000172	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—sarcoma	6.88e-06	0.000172	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—sarcoma	6.85e-06	0.000171	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—sarcoma	6.83e-06	0.00017	CcSEcCtD
Epirubicin—Asthenia—Etoposide—sarcoma	6.81e-06	0.00017	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—sarcoma	6.81e-06	0.00017	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—sarcoma	6.8e-06	0.000169	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—sarcoma	6.78e-06	0.000169	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ENO2—sarcoma	6.73e-06	0.000602	CbGpPWpGaD
Epirubicin—Pruritus—Etoposide—sarcoma	6.72e-06	0.000168	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—HBA1—sarcoma	6.68e-06	0.000598	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—sarcoma	6.68e-06	0.000167	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—ENO2—sarcoma	6.6e-06	0.00059	CbGpPWpGaD
Epirubicin—Erythema multiforme—Doxorubicin—sarcoma	6.56e-06	0.000163	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—HBA1—sarcoma	6.56e-06	0.000586	CbGpPWpGaD
Epirubicin—Diarrhoea—Etoposide—sarcoma	6.5e-06	0.000162	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—sarcoma	6.48e-06	0.000162	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—sarcoma	6.46e-06	0.000161	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—sarcoma	6.43e-06	0.00016	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—sarcoma	6.43e-06	0.00016	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MDM2—sarcoma	6.4e-06	0.000573	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MYC—sarcoma	6.4e-06	0.000572	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ENO2—sarcoma	6.29e-06	0.000563	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—sarcoma	6.29e-06	0.000157	CcSEcCtD
Epirubicin—Dizziness—Etoposide—sarcoma	6.28e-06	0.000157	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—sarcoma	6.26e-06	0.000156	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—sarcoma	6.25e-06	0.000156	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCND1—sarcoma	6.24e-06	0.000558	CbGpPWpGaD
Epirubicin—Chills—Doxorubicin—sarcoma	6.22e-06	0.000155	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—sarcoma	6.19e-06	0.000154	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—sarcoma	6.13e-06	0.000153	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—sarcoma	6.07e-06	0.000151	CcSEcCtD
Epirubicin—Vomiting—Etoposide—sarcoma	6.04e-06	0.000151	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—sarcoma	6.04e-06	0.00015	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—sarcoma	6.04e-06	0.00015	CcSEcCtD
Epirubicin—Rash—Etoposide—sarcoma	5.99e-06	0.000149	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—sarcoma	5.98e-06	0.000149	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFC—sarcoma	5.96e-06	0.000533	CbGpPWpGaD
Epirubicin—Headache—Etoposide—sarcoma	5.95e-06	0.000148	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—sarcoma	5.95e-06	0.000148	CcSEcCtD
Epirubicin—Tension—Doxorubicin—sarcoma	5.92e-06	0.000148	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—sarcoma	5.91e-06	0.000147	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—sarcoma	5.86e-06	0.000146	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—sarcoma	5.84e-06	0.000146	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—sarcoma	5.8e-06	0.000145	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—PLCG1—sarcoma	5.71e-06	0.00051	CbGpPWpGaD
Epirubicin—Vision blurred—Doxorubicin—sarcoma	5.69e-06	0.000142	CcSEcCtD
Epirubicin—Nausea—Etoposide—sarcoma	5.64e-06	0.000141	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—sarcoma	5.6e-06	0.00014	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—PLCG1—sarcoma	5.6e-06	0.000501	CbGpPWpGaD
Epirubicin—Anaemia—Doxorubicin—sarcoma	5.58e-06	0.000139	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—sarcoma	5.58e-06	0.000499	CbGpPWpGaD
Epirubicin—Agitation—Doxorubicin—sarcoma	5.55e-06	0.000138	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—sarcoma	5.44e-06	0.000136	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—sarcoma	5.42e-06	0.000135	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—sarcoma	5.41e-06	0.000135	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—sarcoma	5.4e-06	0.000135	CcSEcCtD
Epirubicin—ABCC1—Disease—PLCG1—sarcoma	5.34e-06	0.000478	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—sarcoma	5.33e-06	0.000133	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—sarcoma	5.3e-06	0.000132	CcSEcCtD
Epirubicin—ABCC1—Metabolism—ENO2—sarcoma	5.27e-06	0.000471	CbGpPWpGaD
Epirubicin—Cough—Doxorubicin—sarcoma	5.27e-06	0.000131	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TP53—sarcoma	5.25e-06	0.00047	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IL2—sarcoma	5.25e-06	0.00047	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—HBA1—sarcoma	5.24e-06	0.000468	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—sarcoma	5.23e-06	0.00013	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—sarcoma	5.21e-06	0.00013	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—sarcoma	5.14e-06	0.000128	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—sarcoma	5.14e-06	0.000128	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—sarcoma	5.14e-06	0.000128	CcSEcCtD
Epirubicin—ABCC1—Disease—CXCR4—sarcoma	5.13e-06	0.000459	CbGpPWpGaD
Epirubicin—Anxiety—Doxorubicin—sarcoma	5.12e-06	0.000128	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	5.1e-06	0.000127	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—sarcoma	5.08e-06	0.000127	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—sarcoma	5.03e-06	0.000125	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—sarcoma	5e-06	0.000447	CbGpPWpGaD
Epirubicin—Confusional state—Doxorubicin—sarcoma	4.97e-06	0.000124	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—sarcoma	4.93e-06	0.000123	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—sarcoma	4.93e-06	0.000123	CcSEcCtD
Epirubicin—Infection—Doxorubicin—sarcoma	4.89e-06	0.000122	CcSEcCtD
Epirubicin—Shock—Doxorubicin—sarcoma	4.85e-06	0.000121	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—sarcoma	4.83e-06	0.00012	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—sarcoma	4.82e-06	0.00012	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—sarcoma	4.81e-06	0.00012	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—sarcoma	4.78e-06	0.000119	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—sarcoma	4.76e-06	0.000119	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FLT1—sarcoma	4.76e-06	0.000426	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—sarcoma	4.7e-06	0.000117	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PLCG1—sarcoma	4.68e-06	0.000419	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—sarcoma	4.6e-06	0.000115	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—SRC—sarcoma	4.58e-06	0.00041	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCR4—sarcoma	4.5e-06	0.000402	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—sarcoma	4.49e-06	0.000112	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MYC—sarcoma	4.47e-06	0.0004	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PLCG1—sarcoma	4.47e-06	0.0004	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—sarcoma	4.46e-06	0.000399	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—sarcoma	4.46e-06	0.000111	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—ATF1—sarcoma	4.45e-06	0.000398	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—sarcoma	4.42e-06	0.00011	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—NRAS—sarcoma	4.41e-06	0.000394	CbGpPWpGaD
Epirubicin—Dyspnoea—Doxorubicin—sarcoma	4.39e-06	0.000109	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—sarcoma	4.38e-06	0.000109	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—sarcoma	4.34e-06	0.000108	CcSEcCtD
Epirubicin—Decreased appetite—Doxorubicin—sarcoma	4.28e-06	0.000107	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—sarcoma	4.25e-06	0.000106	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—sarcoma	4.25e-06	0.000106	CcSEcCtD
Epirubicin—Pain—Doxorubicin—sarcoma	4.21e-06	0.000105	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—sarcoma	4.21e-06	0.000105	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CREB1—sarcoma	4.08e-06	0.000365	CbGpPWpGaD
Epirubicin—Feeling abnormal—Doxorubicin—sarcoma	4.06e-06	0.000101	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—sarcoma	4.03e-06	0.0001	CcSEcCtD
Epirubicin—Urticaria—Doxorubicin—sarcoma	3.91e-06	9.76e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—sarcoma	3.89e-06	9.71e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—sarcoma	3.89e-06	9.71e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—KRAS—sarcoma	3.79e-06	0.000339	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FOXO1—sarcoma	3.79e-06	0.000339	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PDGFRB—sarcoma	3.78e-06	0.000338	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PDGFRA—sarcoma	3.72e-06	0.000333	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—sarcoma	3.67e-06	0.000329	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—sarcoma	3.63e-06	9.05e-05	CcSEcCtD
Epirubicin—Asthenia—Doxorubicin—sarcoma	3.53e-06	8.81e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—sarcoma	3.49e-06	0.000312	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—sarcoma	3.48e-06	8.69e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—TP53—sarcoma	3.37e-06	0.000302	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—sarcoma	3.37e-06	8.4e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO1—sarcoma	3.32e-06	0.000297	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFRB—sarcoma	3.32e-06	0.000296	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFRA—sarcoma	3.26e-06	0.000292	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—sarcoma	3.26e-06	8.12e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—HRAS—sarcoma	3.23e-06	0.000288	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—sarcoma	3.13e-06	7.81e-05	CcSEcCtD
Epirubicin—Rash—Doxorubicin—sarcoma	3.11e-06	7.74e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—sarcoma	3.1e-06	7.74e-05	CcSEcCtD
Epirubicin—Headache—Doxorubicin—sarcoma	3.09e-06	7.69e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—sarcoma	3.01e-06	0.00027	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—sarcoma	2.93e-06	7.29e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—KIT—sarcoma	2.89e-06	0.000258	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CREB1—sarcoma	2.75e-06	0.000246	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KDR—sarcoma	2.75e-06	0.000246	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—sarcoma	2.53e-06	0.000226	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—sarcoma	2.53e-06	0.000226	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CREB1—sarcoma	2.41e-06	0.000215	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—sarcoma	2.31e-06	0.000206	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—sarcoma	2.27e-06	0.000203	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—sarcoma	2.18e-06	0.000195	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—sarcoma	1.99e-06	0.000178	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—sarcoma	1.96e-06	0.000175	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—sarcoma	1.85e-06	0.000166	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—sarcoma	1.78e-06	0.000159	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—sarcoma	1.77e-06	0.000159	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—sarcoma	1.74e-06	0.000155	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—sarcoma	1.73e-06	0.000155	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—sarcoma	1.72e-06	0.000154	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—sarcoma	1.71e-06	0.000153	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—sarcoma	1.59e-06	0.000142	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—sarcoma	1.55e-06	0.000139	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—sarcoma	1.55e-06	0.000139	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—sarcoma	1.51e-06	0.000135	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—sarcoma	1.49e-06	0.000134	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—sarcoma	1.47e-06	0.000131	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—sarcoma	1.39e-06	0.000125	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—sarcoma	1.36e-06	0.000122	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—sarcoma	1.29e-06	0.000115	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—sarcoma	1.25e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—sarcoma	1.14e-06	0.000102	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—sarcoma	1.09e-06	9.78e-05	CbGpPWpGaD
